Hélène Malka-Mahieu

hm.aglaia@gmail.com
8, allée des jardins
78430 – Louveciennes
France
06/12/1985
French Nationality
+33-6-18-19-86-98



WORK EXPERIENCE

April 2023 – Today — **CEO & Co-fondatrice - Peekcell**

Jan 2022 – Feb 2023 — **Head of Research and Partnerships - BioSerenity**
Leading scientific projects in different medical areas (e.g neurology, urology, gastro enterology, psychiatry, cardiology), collaborations with partners (hospitals, academics, and pharmaceutical lab) and clinical studies.

May 2020 – Dec 2021 — **Innovation Project Manager - BioSerenity**
Lead of 2 R&D projects: Implementation of new technologies to monitor urinary or cardio pathologies.

Feb 2019-Feb 2020 — **CEO & Co-fondatrice - Aglaia Therapeutics**
Set up of a start-up (health tech) in RNA biology dedicated to innovative targeted therapies development. These new therapies decrease substantially the percentage of relapse after chemotherapy (targeted therapies and immunotherapies) in melanoma.

Jan 2016 – May 2019 — **Post-Doctoral researcher – Curie Institute**
CNRS UMR3348 (Genotoxic stress and cancer) – RNA biology linked to DNA damage team
Project 1 – Role of ncRNA in oncology clinical pathways
Project 2 – Role of LSM14A in P-bodies and stress granules formation

Nov 2011 – Dec 2015 — **PhD in oncology – Gustave Roussy / Paris Saclay University**
INSERM U981 (Predictive biomarkers and new therapeutic strategies)
« Involvement of the translation initiation complex eIF4F in the resistance to MAPK inhibitors

EDUCATION

March –Oct 2019 — **Enrepreuneurship formation** - X-up program
Ecole Polytechnique (Palaiseau)

December 2015 — **PhD in Science (oncology)** (Doctoral School of Oncology Biology Medecine Health)
Paris-Saclay University – *Highest honour*

June 2011 — **Master 2 Gene Cells Development Evolution** – Genome variability speciality
Paris XI Orsay University

June 2009 — **Two Licences**
Versailles St Quentin en Yvelines University (UVSQ)
* Biology – Environment
* Biodiversity - Genetic

SCIENTIFIC PUBLICATIONS * the authors contributed equally to this work

- Shen S, Girault I, Malka-Mahieu H. Robert C, Vagner S. In situ detection of the eIF4F initiation complex in mammalian cells and tissues, ***STAR Protocols***, 2021 Jun
- Shen S, Allard D, Faouzi S, Martineau S., Malka-Mahieu H, .., Vagner S, Robert C. An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells, ***Nature Communication***, 2019 Nov
- Cerezo M*[1], Guemiri R*[1], Druillennec S*[2], Girault I*[2], Malka-Mahieu H*[2], Shen S, …, Vagner S*, Robert C*. The eIF4F Translation Complex Controls T lymphocyte-Induced PD-L1 Expression to Mediate Tumor Immune Escape. ***Nature Medicine***. 2018 Sept
- Malka-Mahieu H*[1], Newman M*[1], Desaubry L, Robert C, Vagner S. Molecular Pathways: The eIF4F Translation Initiation Complex-New Opportunities for Cancer Treatment. ***Clin Cancer Res***. 2017 Jan 1. pii: clincanres.2362.2016.
- Malka-Mahieu H, Girault I, Rubington,.., Vagner S. Robert C. Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines. ***Cell Cycle***. 2016 Sep 16;15(18):2405-9. doi: 10.1080/15384101.2016.1208862.
- Boussemart L*[1], Girault I*[1], Malka-Mahieu H, …, Vagner S, Robert C. Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization. ***Cancer Res***. 2016 Mar 15;76(6):1476-84.
- Sourisseau T, Helissey C, Lefebvre C, Ponsonnailles F, Malka-Mahieu H, Olaussen KA, André F, Vagner S, Soria JC. Translational regulation of the mRNA encoding the ubiquitin peptidase USP1 involved in the DNA damage response as a determinant of Cisplatin resistance. ***Cell Cycle***. 2016;15(2):295-302.
- Basmadjian C, Malka-Mahieu H, Desaubry L. Revision of the Synthesis and Pharmacological Activity of a Reported Translation Inhibitor. ***Anticancer Agents Med Chem***. 2015;15(10):1305-7.
- Boussemart L*[1], Malka-Mahieu H*[1], Girault I*[1],.., Robert C*, Vagner S*. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. ***Nature***. 2014 Sep 4;513(7516):105-9.